IMAPAC
IMAGINE YOUR IMPACT

EVENT BROCHURE

BIOLOGICS MANUFACTURING KOREA 2026

ADC & BIOCONJUGATE EAST ASIA 2026

14 Years of Excellence: East Asia's Biggest Biologics Manufacturing & ADC Conference

17 - 18 September 2026 Songdo Convensia, Incheon, South Korea

OFFICIAL EVENT BROCHURE

https://infohub.imapac.com/bmk-adcbio-2026-brochure

Table of Contents

EVENT CONTACTS

CONFERENCE PRODUCER

Umairoh Nurul Hafifa
umairoh.nurul@imapac.com
+6285600287725

BUSINESS DEVELOPMENT MANAGER

Ana Laxamana
ana.laxamana@imapac.com
+6569836132

Nathan Grace Niño
nathan.grace@imapac.com
+6569836134

EVENT HIGHLIGHTS

600+	180+	50+
ATTENDEES	COMPANIES	SPEAKERS

DATE & VENUE

17 - 18 September 2026

Songdo Convensia
Incheon, South Korea

About the Event

South Korea has firmly established itself as a global biologics powerhouse, driven by strong R&D investment, rapid innovation, and a world-leading biopharma ecosystem. Under the Biologics World Korea 2026 umbrella, two co-located conferences Biologics Manufacturing Korea (#BMK2026), now in its 14th edition, and ADC & Bioconjugate East Asia (#ADCBio2026) bring together industry leaders from South Korea, Japan, China, and Taiwan.

Together they span the full spectrum of next-generation biologics: upstream and downstream processing, AI-driven manufacturing, regulatory pathways, and supply chain optimisation, alongside ADC development, bioconjugation strategies, CMC considerations, and commercialisation. The result is a fully integrated platform connecting biopharma, CMOs/CROs, regulators, and academia bridging innovation from discovery to market.

WHAT WE'LL COVER

Key Themes

Biomedical Advancements & Innovations

The event explores the latest breakthroughs in biomedical research and technology, highlighting how cutting-edge innovations are transforming healthcare and improving patient outcomes. Discussions will cover emerging medical technologies, advancements in diagnostics, and the future of personalized medicine.

Biopharmaceutical Manufacturing

With the growing demand for high-quality and efficient drug production, the conference delves into modern manufacturing techniques, process optimization, and the integration of automation and AI in pharmaceutical production. Experts will share insights on streamlining operations, ensuring product consistency, and scaling up production to meet global healthcare needs.

ADC & Bioconjugate

The conference will feature insights from East Asia's leading ADC biopharma and big pharma, CMOs/CROs, regulatory authorities, and academic research institutes. Discussions will cover discovery and preclinical advancements, scalable manufacturing strategies, process optimization, CMC considerations, and market access strategies.

Regulatory & Compliance Frameworks

As the biopharmaceutical industry continues to evolve, regulatory requirements remain a crucial aspect of drug development and commercialization. Sessions will address the latest policies, compliance challenges, and strategies for navigating complex regulatory landscapes across different regions

Collaborations & Networking

The event provides a platform for key industry players, researchers, and policymakers to connect and exchange ideas. Topics will include public-private partnerships, industry collaborations, and the role of government initiatives in supporting research and development. Strengthening networks and fostering international cooperation will be key discussion points.

Sustainability & Future Trends

The industry is moving towards more sustainable and environmentally friendly practices, and this theme will highlight innovative solutions for reducing waste, improving energy efficiency, and adopting green technologies. Additionally, experts will share insights on future trends, investment opportunities, and the next big breakthroughs shaping the future of biopharmaceuticals.

Advanced Modalities

The event will spotlight cutting-edge developments in novel therapeutic modalities, RNA therapeutics, cell and gene therapies, and AI-driven bioprocessing. With participation from Korea's leading biologics manufacturers and global industry leaders, this conference is essential for staying ahead in the fast-evolving biologics landscape.

Sponsors & Media Partners

SILVER

BSP PHARMACEUTICALS

Pfanstiehl

BRONZE

Schneider Electric

CYGNUS TECHNOLOGIES part of Maraval LifeSciences

DONGIL BIOTECH

EXHIBITION & NETWORKING

ThermoFisher SCIENTIFIC

NONA BIOSCIENCES

FUJIFILM

YOKOGAWA

onesource

EVONIK Leading Beyond Chemistry

ASSOCIATE

PharmNXT

CELLTRIO

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

2026 SPEAKERS

BMK-2026

Jong Gu Kim
Director, Quality
Lotte Biologics
SOUTH KOREA

Kihyun Park, Ph.D.
Lead Scientist in AAV Process Discovery Part
Samsung Biologics
SOUTH KOREA

Dae Won Kim, Ph.D.
Chief Executive Officer & Founder
ICM Co., Ltd.
SOUTH KOREA

Paul Y. Song
Chief Executive Officer
NKGen Biotech
UNITED STATES

Heechung Kwon
Chief Executive Officer
GencellMed
SOUTH KOREA

Sammi Hsu
Senior Manager
Ever Supreme Biotechnology
TAIWAN

Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas
CEO, Cellafa Biosciences
JAPAN

Cheng Yi (Jerry) Kuo
Assistant General Manager
UWell Biopharma
TAIWAN

Young Jun Seo
CEO
Elonova
SOUTH KOREA

Prof., Dr. Lee, Beom-Jin
Professor
Ajou University
SOUTH KOREA

Chen Hong Hang
Global Solution Architect, Life Science Segment
Schneider Electric
SINGAPORE

Eric Bishop
VP of Research and Development
Cygnus Technologies
UNITED STATES

Hemasunder Reddy
Business Development Director
Pfanstiehl, Inc.
UNITED STATES

Yo Kyung Chung
CTO and Head of R&D
Rophibio
SOUTH KOREA

ADCBIO-2026

Doo Young Jung
Chief Executive Officer
PinotBio
SOUTH KOREA

Yo-Sup Rew
Chief Technology Officer
Intocell
SOUTH KOREA

Wei Han Lee
Director CMC
OBI Pharma
TAIWAN

Won Gyun Ahn
Associate Director
Qurient
SOUTH KOREA

Chung Yi Wu
CEO
CHO Pharma
TAIWAN

Dr. John Luk
CEO & Founder
ArbeleBio
UNITED STATES

Wei Ting Sun
Director R&D
HoneyBear Bioscience
TAIWAN

Akshaya Bansal
Executive Director, ADC Platforms
Hummingbird Bioscience
SINGAPORE

Heon Chang Lim
Director, Formulation
Samsung Biologics
SOUTH KOREA

Yi Yang
CEO & Founder
Glyco-therapy Biotech
CHINA

Giorgio Salciarini
Head of Sales - Technical Business Development
BSP Pharmaceuticals

Shawn Seong
CEO & Founder
Shaperon
SOUTH KOREA

Agenda At A Glance

CONFERENCE DAY 1 | 17 SEPTEMBER 2026		CONFERENCE DAY 2 | 18 SEPTEMBER 2026	
BIOLOGICS MANUFACTURING KOREA 2026	ADC & BIOCONJUGATE EAST ASIA 2026	BIOLOGICS MANUFACTURING KOREA 2026	ADC & BIOCONJUGATE EAST ASIA 2026
Leadership Panel Discussion Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies		**Redefining ADC Therapeutics** Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs	
MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Quality, Scale-Up & CMC Excellence Bridging Development and Commercialisation	**Discovery** Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies	**CAR-T & CAR-NK Therapies Case Studies** Next-Gen Cell Therapy & Preclinical Innovation	**Advancing Payloads and Linker Technologies for Next-Generation ADCs**
LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Case Studies in Advanced Modalities	**Optimizing ADC Target Selection and Engineering for Maximum Efficacy**	**Advancing Gene Therapy** Optimizing Vectors, Editing Technologies, and Smart Manufacturing	
AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Closing Roundtable Session From Design to Delivery: Quality, CMC, and Clinical Insights Shaping the Next Wave of Biologics		**Closing Roundtable Discussion** Next-Generation Modalities: Advancing Cell Therapy, Gene Therapy, and ADCs from Bench to Market	
END OF CONFERENCE DAY 1			

Conference Producer:
Umairoh Nurul Hafifa · umairoh.nurul@imapac.com · +6285600287725

CONFERENCE AGENDA

Day 1

Thursday, 17 September 2026

OPENING THEME

Scaling Biologics & CGT in East Asia

Biologics Manufacturing Korea 2026 | **ADC & Bioconjugate East Asia 2026**

8:50 IMAPAC Opening Remarks

8:55

Chairman Opening Remarks

Yi Yang
CEO & Founder, Glyco-therapy Biotech

Fireside Chat: Scaling Biologics & ADC in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies

9:00

Fireside Chat: Scaling Biologics & ADC in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies

- Innovation across biologics and ADC pipelines: how emerging platforms are driving the next wave of development in East Asia.
- Manufacturing and formulation readiness: quality and formulation challenges specific to scaling biologics and ADC production.
- Bridging innovator and manufacturer priorities: tech transfer, quality alignment, and collaboration as ADC and biologics programs move toward commercial scale.
- Cross-border collaboration and the road ahead: positioning Korea and East Asia's ecosystem for combined biologics and ADC growth.

Shawn Seong
CEO & Founder, Shaperon

Heon Chang Lim
Director, Formulation, Samsung Biologics

Biologics Manufacturing Korea 2026 | ADC & Bioconjugate East Asia 2026

9:40

Arginine-Glutamate as Ideal Excipient for High Concentration Monoclonal Antibody Formulation.

- Need for higher dose of monoclonal antibodies(mAb) formulations
- Arginine-Glutamate a promising candidate to address concerns of aggregation, viscosity, liquid-liquid phase separation and longer storage
- Mechanism driving mAb stability in formulation containing Arginine-Glutamate

Hemasunder Reddy
Business Development Director, Pfanstiehl, Inc.

10:05

Fatty Acid-conjugated "Fattigation" Biomaterials for Improved Physicochemical and Biological Performance

- Fattigation-Fatty acid conjugation
- Synergistic drug delivery strategies
- Redox-sensitive fattigated hyaluronic acid nanoparticles
- Receptor-oriented cancer targeting

Prof., Dr. Lee, Beom-Jin
Professor, Ajou University

10:30

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Biologics Manufacturing Korea 2026

Quality, Scale-Up & CMC Excellence: Bridging Development and Commercialisation

11:15

Data Integrity 2.0 (Strategic Quality Management and Integrated Lifecycle Collaboration, MAH - CDMO - Suppliers)

- The 2026 Regulatory Paradigm Shift
- Building an Honest Orgnizational Foundation from Quality Culture and Metrics perspective
- Lifecycle Collaboration Model between MAH - CDMO – Supplier
- Roadmap to 2026 and beyond

Jong Gu Kim
Director, Quality, Lotte Biologics

ADC & Bioconjugate East Asia 2026

Discovery: Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies

SESSION CHAIR

Yi Yang
CEO & Founder, Glyco-therapy Biotech

11:15

Engineering Next-Generation ADCs through Glycosite-Specific Glycan Design

- Engineering glycan structures to improve ADC potency, stability, and therapeutic index.
- Modulating Fc biology to reduce off-target toxicity while preserving antitumor efficacy.
- Enabling homogeneous bispecific, dual-payload, and next-generation antibody conjugates.
- Translating glycosite-specific conjugation into scalable CMC and manufacturing advantages.

Chung Yi Wu
CEO, CHO Pharma

Biologics Manufacturing Korea 2026

11:40

Building the Digital Foundation for Scalable Biopharma Manufacturing: Unified Operations for Resilience, Compliance, and Efficiency

- Biologics and pharmaceutical manufacturers face increasing pressure to improve operational efficiency, compliance, resilience, and scalability. However, many facilities still rely on fragmented building, utility, and power systems that create silos and limit visibility.
- This talk explores how unified, AI-powered operations can provide a smarter digital foundation for biopharma manufacturing.
- Using Schneider Electric's EcoStruxure Foresight as an example, the session will show how connected facility operations can improve uptime, streamline lifecycle management, support controlled environments, and enable more future-ready, data-driven operations.

Chen Hong Hang
Global Solution Architect, Life Science Segment, Schneider Electric

ADC & Bioconjugate East Asia 2026

11:40

Supporting ADC From IND To The Long Term Commercial Supply: A Step Ahead Against The Challenges Of The Bioconjugates

- Serving the Innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
- Driving ADC Success with Flexible & High-Quality Solutions from Preclinical to Commercial
- Highlights on the approach to support early stage program through robust development studies.
- Ensuring right first-time-approved regulatory submission to save time and costs.

Giorgio Salciarini
Head of Sales - Technical Business Development, BSP Pharmaceuticals

Biologics Manufacturing Korea 2026

11:55

Biosimilar Manufacturing: Integrated CMC Strategies for Global Development and Regulatory Access

- Evolving Biosimilar Market and Regulatory Environment
- Designing Analytical Similarity and CMC as One Integrated Strategy
- Managing Biosimilarity and Comparability from Development through Commercial Manufacturing
- Manufacturing Competitiveness: CoGS, Quality, and Supply Reliability

Yo Kyung Chung
CTO and Head of R&D, Rophibio

12:20

Lunch Break, Exhibition Viewing & 1-1 Attendee Networking

ADC & Bioconjugate East Asia 2026

12:05

PdRaxane: A NanoMab Drug Conjugate Addressing the Limitations of Classical ADCs

- Active tumor routing and retention through gp60, SPARC and PD-L1 targeting
- Non-covalent NanoMab assembly overcoming conventional conjugation and linker limitations
- Preclinical data show similar activity at 1/10 the dose — a dose-dependent reduction in toxicity that favors long-term therapy
- Integrated checkpoint blockade and nab-paclitaxel delivery remodels the immunosuppressive TME into a hot phenotype with increased effector T-cell activation

Shawn Seong
CEO & Founder, Shaperon

12:30

Lunch Break, Exhibition Viewing & 1-1 Attendee Networking

Biologics Manufacturing Korea 2026

Case Studies in Advanced Modalities

1:45

Chemical Engineering of Next-Generation mRNA Platforms for RNA Therapeutics

- Innovative chemical engineering of mRNA to enhance stability, translation efficiency, and therapeutic performance
- Next-generation mRNA platform technologies beyond vaccines
- Expanding RNA therapeutics for oncology, autoimmune diseases, and other therapeutic applications
- Future opportunities for collaboration in next-generation RNA medicines across Asia

Young Jun Seo
CEO, Elonova

2:10

Advanced Orthogonal Analysis of HCP using Mass Spectrometry

- Overview of Mass Spectrometry in HCP Analytics
- Advantages of MS in Coverage Analysis
- Identification of HCP in DS
- Relative and Absolute Quantification of individual HCPs using MS

Eric Bishop
VP of Research and Development, Cygnus Technologies

ADC & Bioconjugate East Asia 2026

Optimizing ADC Target Selection and Engineering for Maximum Efficacy

1:45

From Site-Specific Conjugation to Dual-Payload ADCs: Enzymatic Strategies for Next-Generation Antibody Therapeutics

- Harnessing enzymatic glycan remodeling for precise antibody conjugation.
- Controlling conjugation sites and drug-to-antibody ratios.
- Stepwise conjugation strategies for dual-payload ADCs with tunable payload ratios.
- Expanding the design space of next-generation antibody conjugates.

Wei Ting Sun
Director R&D, HoneyBear Bioscience

2:10

Expanding the Therapeutic Index and Overcoming Resistance via Glycan Conjugation

- Enhanced safety & infinite creation through YTConju®
- Enhanced efficacy through a novel TopoI
- Conquering resistance by synergistic dual-payload combinations

Yi Yang
CEO & Founder, Glyco-therapy Biotech

Biologics Manufacturing Korea 2026

2:25

Enhancing AAV Manufacturing Yield Through a Promoter-Optimized Mini-Helper Plasmid

- Developed a Mini-Helper plasmid - a minimized, promoter-optimized helper plasmid retaining only essential AAV helper genes.
- Boosted AAV productivity — achieved 2.0–6.5× higher AAV titers depending on serotype, with reduced cost and no compromise in particle quality.
- Validated scalability — consistent performance from flask scale up to 2 L and 200 L bioreactors, demonstrating a scalable, cost-effective AAV manufacturing solution.

Kihyun Park, Ph.D.
Lead Scientist in AAV Process Discovery Part, Samsung Biologics

ADC & Bioconjugate East Asia 2026

2:35

Formulation / Lyophilization Case Study for ADC Molecules: Challenges and Breakthrough

- ADC
- Formulation
- Lyophilization

Heon Chang Lim
Director, Formulation, Samsung Biologics

3:00 **Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking**

3:30

Closing Roundtable Session: From Design to Delivery: Quality, CMC, and Clinical Insights Shaping the Next Wave of Biologics

1. Quality by Design vs. Quality by Inspection: Closing the Gap Between Theory and Practice
2. CMC Risk Management: Identifying and De-Risking Critical Process Parameters Early
3. CDMO Selection: Beyond Capacity: What Really Predicts a Successful Partnership?
4. Resistance Mechanisms and Sequencing ADCs in Treatment Paradigms
5. Glycan Engineering for Improved ADC and Biologics Efficacy

4:30

Chairman Closing Remarks

4:35 **END OF CONFERENCE DAY 1**

Conference Producer:
Umairoh Nurul Hafifa · umairoh.nurul@imapac.com · +6285600287725

CONFERENCE AGENDA

Day 2

Friday, 18 September 2026

OPENING THEME

Scaling Biologics & CGT in East Asia

Biologics Manufacturing Korea 2026

8:50 IMAPAC's Opening Address

8:55 **Chairman's Opening Address**

Wei Han Lee
Director CMC, OBI Pharma

ADC & Bioconjugate East Asia 2026

8:50 IMAPAC's Opening Address

8:55 **Chairman's Opening Address**

Redefining ADC Therapeutics: Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs

Exhibition Hall, Ballroom B

9:00

Integrating Enzymatic Glycan Conjugation, Scalable One-Pot Manufacturing, and Advanced Analytical Control Strategies for Mono- and Dual-Payload ADCs

- Overcoming the limitations of traditional random conjugation through site-specific glycan remodeling and innovative linker technologies.
- Transforming enzymatic conjugation into a cost-effective, highly robust, and industrially scalable manufacturing process.
- Establishing analytical foundations, DAR characterization, and control strategies for mono- and dual-payload ADCs.

Wei Han Lee
Director CMC, OBI Pharma

Biologics Manufacturing Korea 2026 | ADC & Bioconjugate East Asia 2026

9:25

Beyond BsADCs: From Better Delivery to Checkmate Killing with Novel Proteasome Inhibitor Payload

- The ADC Evolution & The Lethality Gap
- The Next Wave: Overcoming Resistance
- Pioneering Novel Payloads (The QLi5 Platform)

Won Gyun Ahn
Associate Director, Qurient

9:50

OHPAS™, PMT™, and Nexatecan™ Technologies for Enhanced ADC Efficacy and Safety

- OHPAS™ linker design and PMT™ mechanism
- Proproprietary Nexatecan™ and iso-Nexatecan™ TOP1 inhibitor payloads
- Next-generation ADC development enabled by IntoCell's platform

Yo-Sup Rew
Chief Technology Officer, Intocell

10:15

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall, Ballroom B

Biologics Manufacturing Korea 2026

CAR-T & CAR-NK Therapies Case Studies: Next-Gen Cell Therapy & Preclinical Innovation

SESSION CHAIR

Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences

11:00

ICM-203 AAV Gene Therapy as a Promising DMOAD Candidate for OA Treatment

- Target (Nkx3.2) discovery and validation for OA treatment
- Preclinical validation of ICM-203 for DMOAD activity
- First-in-human clinical development of ICM-203

Dae Won Kim, Ph.D.
Chief Executive Officer & Founder, ICM Co., Ltd.

ADC & Bioconjugate East Asia 2026

Advancing Payloads and Linker Technologies for Next-Generation ADCs

11:00

Dual-Payload ADC Platform: Advancing Rational Payload Combinations to Address Resistance

- Addressing ADC payload resistance through rationally selected dual-payload combinations.
- Integrating payload selection, conjugation strategy, linker chemistry, and antibody engineering to optimize efficacy and minimize off-target toxicity.
- Streamlining development and manufacturing to accelerate candidate-to-IND progression.

Akshaya Bansal
Executive Director, ADC Platforms, Hummingbird Bioscience

Biologics Manufacturing Korea 2026

11:25

Use of Troculeucel (Cryopreserved Enhanced Autologous NK Cell Therapy) for Neurodegenerative Diseases

- Troculeucel's mechanism of action in reducing CSF neuroinflammatory and protein biomarkers.
- Reviewing the early clinical efficacy of Troculeucel in AD, PD, and FTD patients.
- Discuss regulatory landscape in Asia to expedite development and commercialization of Troculeucel

Paul Y. Song
Chief Executive Officer, NKGen Biotech

ADC & Bioconjugate East Asia 2026

11:25

Combining Payload Selection, Linker Design and Site-specific Conjugation for Dual Payload ADC Development

- Importance of payload selection for the design of dual payload ADC - pharmacology and physicochemical properties perspective
- Exploitation of novel linkers to expand the applicable payload scope
- Improving stability of dual payload ADCs by applying site-specific conjugation

Doo Young Jung
Chief Executive Officer, PinotBio

Biologics Manufacturing Korea 2026 | ADC & Bioconjugate East Asia 2026

11:50

Driving Innovation in Cell Therapy Manufacturing with AI and Robotics: From Process Optimization to Regulatory-Ready Platforms

- Feasibility study results on AI-driven process optimization for iPSC-derived NK cell production, utilizing machine learning to analyze process data generated by the dual-arm LabDroid "Maholo" automation system.
- The discussion will cover how AI-enabled data analysis and robotic automation can improve yield, enhance batch-to-batch consistency, and support robust cell quality in advanced cell therapy manufacturing.
- Outline a regulatory strategy for implementing robotic automation in GMP environments, including key considerations from interactions with regulatory agencies.

Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences

12:15

Lunch Break, Exhibition Viewing & 1-1 Attendee Networking

Conference Producer:
Umairoh Nurul Hafifa · umairoh.nurul@imapac.com · +6285600287725

Advancing Gene Therapy: Optimizing Vectors, Editing Technologies, and Smart Manufacturing

Exhibition Hall, Ballroom A

SESSION CHAIR

Heechung Kwon
Chief Executive Officer, GencellMed

1:45

Advancing Allogeneic CAR-T for Solid Tumors: From Phase II Clinical Development to Next-Generation In Vivo CAR-T

- Clinical progress and Phase IIa development strategy of CAR001, an allogeneic off-the-shelf CAR-T therapy for solid tumors.
- Emerging clinical insights from recurrent glioblastoma and other solid tumor indications.
- Manufacturing and scalability considerations for next-generation allogeneic cell therapies.
- Leveraging clinical experience to develop EXO001, an in vivo CAR-T platform.

Sammi Hsu
Senior Manager, Ever Supreme Biotechnology

2:10

Clinical Development of CRA-T Cell Therapy: Manufacturing, Formulation and Administration.

Cheng Yi (Jerry) Kuo
Assistant General Manager, UWell Biopharma

2:35

Development of an Oncolytic Gene Therapy for Peritoneal Cancer Using Retargeted HSV Vectors

- To strictly redirect oncolytic herpes simplex virus (oHSV) to cancer-specific antigens, Gencellmed developed the SMART™ HSV retargeting platform, a novel, double-retargeted oHSV system.
- GencellMed's lead oncology asset GCM-101: Unlike conventional oHSVs that largely retain natural viral tropism, GCM-101 is engineered to exclusively enter EpCAM-expressing cancer cells, thereby maximizing tumor selectivity and minimizing off-target infection of normal cells.
- Preclinical evaluations of GCM-101's broad therapeutic potential across solid tumors with high EpCAM expression, including ovarian, colorectal, gastric, pancreatic, and lung cancers.

Heechung Kwon
Chief Executive Officer, GencellMed

3:00

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Premier Ballroom A

Day 2

Friday, 18 September 2026

Biologics Manufacturing Korea 2026 | **ADC & Bioconjugate East Asia 2026**

3:30

Closing Roundtable Session - Navigating Complexity: Practical Solutions for Cell, Gene, and ADC Therapeutics in East Asia

1. Cell Therapy Clinical Development: What Works and What Doesn't

Cheng Yi (Jerry) Kuo
Assistant General Manager, UWell Biopharma

2. Next-Gen Payload and Linker Innovation: What's Actually Moving the Needle Post-ADC 1.0

Sammi Hsu
Senior Manager, Ever Supreme Biotechnology

3. Beyond CAR-T: Overcoming Manufacturing and Access Bottlenecks in Solid Tumor Cell Therapies

Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences

4:30

Chairman Closing Remarks

4:35

END OF CONFERENCE

Expected Audience Snapshot

70%
ATTENDANCE FROM KOREAN BIOPHARMAS

80%
DECISION MAKERS

BY PROFILE

- Korea Biopharma — 50%
- Other Asian & International Biopharma — 20%
- CMOs — 15%
- Technology & Service Providers — 10%
- Academic & Research Institutes — 5%

BY JOB TITLE

- VPs & Directors of Process Development — 25%
- USP & DSP Specialists & Researchers — 25%
- Head of Quality Assurance & Analytics — 20%
- Head of Manufacturing & Bioprocessing — 15%
- Business Development & Marketing — 15%

BY GEOGRAPHY

- 5% USA
- 3% Europe
- 3% Taiwan & India
- 3% South East Asia
- 5% Japan
- 5% Singapore
- 68% South Korea
- 3% Other

Who Should Sponsor?

BIOMANUFACTURING SOFTWARE
CELL CULTURE AND FERMENTATION
PROCESS OPTIMIZATION
CRYOPRESERVATION
HIGH-THROUGHPUT SCREENING
MICROFLUIDICS
BIOSENSOR TECHNOLOGY
GENE THERAPY TECHNOLOGY
SINGLE-USE TOOLS
DRUG DELIVERY
BIOPROCESSING EQUIPMENT
CELL LINE DEVELOPMENT
NEXT-GENERATION SEQUENCING
BIOINFORMATICS
BIOSENSOR TECHNOLOGY
AUTOMATION AND ROBOTICS
3D BIOPRINTING
GENE EDITING
CONTINUOUS MANUFACTURING
LINKER & PAYLOAD DEVELOPMENT
PROCESS DEVELOPMENT & CDMOS
FORMULATION DEVELOPMENT
BIOINFORMATICS & COMPUTATIONAL MODELLING
REGULATORY SUPPORT
BIOCONJUGATION CHEMISTRY
PRE-CLINICAL DEVELOPMENT & CLINICAL TRIAL SUPPLY & MANAGEMENT & CROS
FILL-FINISH PACKAGING
CDMOS, CROS & ADC SERVICE PROVIDERS
ANALYTICAL TESTING & QUALITY CONTROL

Why Sponsor

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases for German Market

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

Our Past Partners

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

MARK YOUR CALENDAR

Save the Date

17–18 SEP 2026

Songdo Convensia

BMK & ADCBio 2026 Brochure

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific — biopharmaceutical conferences, summits, and exhibitions for the year ahead. →

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

Registration Form

CATEGORY	EARLY BIRD (By 27 March 2026)	REGISTRATION (By 29 May 2026)	STANDARD (By 31 July 2026)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595

BRING YOUR TEAM - Group Discount

Asia & International Biopharma

☐ Buy 2, Get 3 passes
☐ Buy 3, Get 5 passes

Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes.

INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount.

- Access to all conference proceedings for up to 30 days.
- Site Tour Package is applicable only with the purchase of a conference pass.

Standard Package Group Discount

3 Delegates Save 10% ☐ 5 Delegates Save 20% ☐ 6+ Delegates Save 25% ☐

EVENT VENUE

Songdo Convensia, Incheon, South Korea

17 - 18 September 2026

3 EASY WAYS TO REGISTER

Online
https://www.imapac.com/events/biologics-manufacturing-korea-2026#register

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at https://www.imapac.com/events/biologics-manufacturing-korea-2026#register

Name on Card _____ Card Number _____
Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received.
Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers).
Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

E: ana.laxamana@imapac.com | nathan.grace@imapac.com C: +65 6983 6132 | +65 6983 6134

Registration Form

ADC & BIOCONJUGATE EAST ASIA 2026

CATEGORY	EARLY BIRD (By 27 March 2026)	REGISTRATION (By 29 May 2026)	STANDARD (By 31 July 2026)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595

BRING YOUR TEAM - Group Discount

Asia & International Biopharma

☐ Buy 2, Get 3 passes
☐ Buy 3, Get 5 passes

Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes.

INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount.

- Access to all conference proceedings for up to 30 days.
- Site Tour Package is applicable only with the purchase of a conference pass.

Standard Package Group Discount

3 Delegates Save 10% ☐ 5 Delegates Save 20% ☐ 6+ Delegates Save 25% ☐

EVENT VENUE

Songdo Convensia, Incheon, South Korea

17 - 18 September 2026

3 EASY WAYS TO REGISTER

Online
https://www.imapac.com/events/adc-bioconjugate-east-asia-2026#register

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at https://www.imapac.com/events/adc-bioconjugate-east-asia-2026#register

Name on Card _____ Card Number _____
Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received.
Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers).
Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

E: ana.laxamana@imapac.com | nathan.grace@imapac.com C: +65 6983 6132 | +65 6983 6134

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

IMAPAC
IMAGINE YOUR IMPACT

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd